Profile data is unavailable for this security.
About the company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
- Revenue in USD (TTM)68.56m
- Net income in USD-437.99m
- Incorporated2016
- Employees367.00
- LocationVir Biotechnology Inc1800 OWENS STREET, SUITE 900SAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 906-4324
- Fax+1 (302) 636-5454
- Websitehttps://www.vir.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.35bn | 69.00 | -- | 2.64 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.37bn | 130.00 | -- | 5.49 | -- | 91.47 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -129.47m | 1.39bn | 104.00 | -- | 3.56 | -- | -- | -1.51 | -1.51 | 0.00 | 3.90 | 0.00 | -- | -- | 0.00 | -37.91 | -36.88 | -40.60 | -39.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.27 | -- | 1.31 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.48bn | 43.00 | -- | 3.80 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| Vir Biotechnology Inc | 68.56m | -437.99m | 1.49bn | 367.00 | -- | 1.70 | -- | 21.77 | -3.16 | -3.16 | 0.4949 | 5.49 | 0.0571 | -- | -- | 186,801.10 | -36.47 | -5.87 | -40.01 | -6.81 | 99.96 | 92.66 | -638.87 | -18.05 | -- | -- | 0.00 | -- | -7.61 | -2.14 | 16.09 | -- | -5.90 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.50bn | 31.00 | -- | 18.62 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Sionna Therapeutics Inc | 0.00 | -75.27m | 1.51bn | 59.00 | -- | 4.94 | -- | -- | -1.70 | -1.70 | 0.00 | 6.86 | 0.00 | -- | -- | 0.00 | -29.42 | -- | -30.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.01 | -- | -- | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.52bn | 136.00 | -- | -- | -- | 8.97 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.55bn | 155.00 | -- | 8.04 | -- | 23.34 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 263.50m | -390.98m | 1.56bn | 975.00 | -- | 2.23 | -- | 5.93 | -1.12 | -1.12 | 0.7376 | 1.70 | 0.289 | 3.64 | 3.47 | 270,258.50 | -42.88 | -48.97 | -50.03 | -56.18 | 28.66 | -- | -148.38 | -453.71 | 2.83 | -- | 0.0014 | -- | 60.60 | -- | -5.05 | -- | -6.28 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.57bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Ardelyx Inc | 407.32m | -61.60m | 1.59bn | 489.00 | -- | 9.47 | -- | 3.90 | -0.2576 | -0.2576 | 1.69 | 0.6832 | 0.8691 | 2.03 | 6.29 | 832,965.30 | -13.14 | -27.52 | -15.98 | -35.02 | 90.29 | 87.82 | -15.12 | -42.28 | 4.11 | -2.04 | 0.5485 | -- | 22.09 | 121.90 | -57.40 | -- | 35.72 | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.61bn | 26.00 | -- | 8.49 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.63bn | 317.00 | -- | 2.99 | -- | 19.36 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.63bn | 28.00 | -- | 3.37 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
Data as of Mar 03 2026. Currency figures normalised to Vir Biotechnology Inc's reporting currency: US Dollar USD
32.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 14.08m | 10.12% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.83m | 8.50% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 6.23m | 4.48% |
| FIAM LLCas of 31 Dec 2025 | 2.60m | 1.87% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.42m | 1.74% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.33m | 1.67% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.96m | 1.41% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 1.50m | 1.08% |
| abrdn, Inc.as of 31 Dec 2025 | 1.39m | 1.00% |
| Balyasny Asset Management LPas of 31 Dec 2025 | 1.37m | 0.98% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
